Title

Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail
A Randomized, Double-Blind, Parallel-Group,Multicenter, Dose-Response, Vehicle-Controlled Study of the Safety and Efficacy of NB-002 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    nb-002 ...
  • Study Participants

    443
The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.
The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.
Study Started
Jan 31
2007
Primary Completion
Oct 31
2008
Study Completion
Oct 31
2008
Last Update
May 23
2013
Estimate

Drug NB-002

Drug Vehicle control

NB-002 0.5% BID Experimental

Vehicle control Sham Comparator

NB-002 0.25% BID Experimental

NB-002 0.5% QD Experimental

Criteria

Inclusion Criteria:

are healthy males or females between the ages of 18 and 75 years of age;
have a clinical diagnosis of mild to moderate DSO in the nail of at least one great toe, involving 25%-67% of the nail, without lunular or proximal involvement;
positive mycology results (ie, KOH test and culture of a dermatophyte) from the target great toenail;
refrain from using any lotions, creams, liquids, or polish on treated toenails or on the skin immediately adjacent to the toenails during the treatment period unless directed to do so by the investigator;
are willing to refrain from using topical steroids or topical antifungals on toenails or the skin immediately adjacent to the toenails; or systemic antifungals for the duration of the study;

Exclusion Criteria:

females who are pregnant, plan to become pregnant during the study, or are nursing a child;
are hypersensitive to topical creams, ointments, medications, or surfactants;
have received systemic antifungal therapy for any reason within 3 months, or topical antifungal therapy on the toenails or skin immediately adjacent to the toenails within 3 weeks prior to the start of the study; or
have taken any investigational drug within 4 weeks prior to the start of the study.

Other protocol-defined inclusion/exclusion criteria may apply.
No Results Posted